PI: Daniel A. Hamstra, PhD, MD
Approximately 10-30% of men who undergo external beam radiation for localized prostate cancer see rising PSA scores following treatment. Some of these men need androgen deprivation therapy (ADT) as salvage treatment. ADT is not curative and has significant side effects that impact quality of life (QOL). These facts must be balanced against its clinical need.
The decision to initiate hormonal therapy is driven more by patient anxiety and less by clinical parameters. Thus, men need to better understand how their PSA values and likelihood of recurrence will change over time.
A novel computer model, based on 2,386 patients previously treated, will provide this information. This project aims to develop and test methods of communicating this information to patients and to determine how patients use it in their treatment decisions.
(09/01/2010 - 08/31/2012)